Literature DB >> 3465537

The role of cholesterol in the glucocorticoid-mediated inhibition of cell cycle progression in human acute lymphoblastic leukemia cells.

J L Cutts, G Melnykovych.   

Abstract

Two glucocorticoid receptor-containing clones of human acute lymphoblastic leukemia, one (CEM-C7) sensitive and one (CEM-C1) resistant to dexamethasone (dex) were studied in an effort to identify the time course of the biochemical changes responsible for dex-induced growth inhibition of CEM-C7 cells. Cells were synchronized by treatment with 0.25 mM (C7) or 0.50 mM (C1) thymidine for 12 h followed by 0.025 micrograms/ml (C7) or 0.050 micrograms/ml (C1) colcemid for 12 h, then released either in the presence or absence of 1 microM dex. The inhibition of cellular proliferation which occurs at 48 h after release in the dex-treated CEM-C7 cells was preceded by an inhibition of acetate incorporation into cholesterol, first evident at 24 h, inhibition of protein synthesis at 30 h, and the development of a cell cycle block in G1 at 36 h. No inhibition of any of these parameters was seen in the resistant CEM-C1 cells. Thus the inhibition of cholesterol synthesis in the sensitive cells may be one of the earliest parameters affected by glucocorticoids.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3465537     DOI: 10.1016/0014-4827(87)90419-8

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  3 in total

Review 1.  Apoptosis induced by anticancer drugs.

Authors:  J A Hickman
Journal:  Cancer Metastasis Rev       Date:  1992-09       Impact factor: 9.264

2.  Butyric acid-induced apoptosis of murine thymocytes, splenic T cells, and human Jurkat T cells.

Authors:  T Kurita-Ochiai; K Fukushima; K Ochiai
Journal:  Infect Immun       Date:  1997-01       Impact factor: 3.441

3.  Glucocorticoid resistance in T-lineage acute lymphoblastic leukaemia is associated with a proliferative metabolism.

Authors:  A H Beesley; M J Firth; J Ford; R E Weller; J R Freitas; K U Perera; U R Kees
Journal:  Br J Cancer       Date:  2009-05-12       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.